22
May
2019
From Open Biology to Pharma Leadership: Jay Bradner of Novartis on The Long Run
Today’s guest on The Long Run is Jay Bradner. Jay is the president of the Novartis Institutes for Biomedical Research (NIBR). This is one of the heavyweight organizations in Big Pharma industry R&D. When Novartis planted this operation in the heart of Cambridge, Mass. more than a decade ago, it was the start of a trend toward Big Pharma R&D... Read More
16
May
2019
Amgen Swings for the RAS Fence, Gilead’s Grilling on Price, & Agios Enlarges the Pie
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
May
2019
An Elephant for Immunology Drugs: Sheila Gujrathi on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
May
2019
Thank You, Biotech: Kili Climb to Fight Has Crushed Its $1m Goal for Cancer Research
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Apr
2019
Blazing a New Trail in Psychiatry & Women’s Health: Jeff Jonas on The Long Run
Today’s guest on The Long Run is Jeff Jonas. Jeff is the CEO of Cambridge, Mass.-based Sage Therapeutics. The company made big news – front page of the New York Times – a month ago. That’s when it won FDA clearance to sell the first drug ever for postpartum depression. It’s a big story for a number of reasons. Postpartum... Read More
9
Apr
2019
The Road Less Traveled in Glycoscience: Carolyn Bertozzi on The Long Run
Today’s guest on The Long Run is Carolyn Bertozzi. She is a professor of chemistry at Stanford University, and an entrepreneur. Her research is focused on glycans – the beautiful and bewilderingly complicated sugar molecule structures attached to proteins. These carbohydrates are often underappreciated by biologists, and “orthogonal” to the way many think. But glycans are known to play a... Read More
9
Apr
2019
Foundation, Flatiron Cross the Genotype-Phenotype Chasm, Show Clinical Cancer Genome Database at Work
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Apr
2019
IFM Nails Second Big Deal, Selling NLRP3 Inhibitors to Novartis for $310M Upfront
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Mar
2019
Thermo Bets on Viral Vector Manufacturing, Precision & Genfit’s IPOs, & Not Much Else
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Mar
2019
Life of a Scientific Entrepreneur: Bob Langer of MIT on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Mar
2019
Sage’s Depression Triumph, Biogen’s Alzheimer’s Defeat, & Apple Watch Hype
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Mar
2019
Sharpless in the Saddle, NIH Threatened Again, & PBMs Prep for Senate Scrutiny
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Mar
2019
Seeing Lots of Single Cells, Up Close: Serge Saxonov of 10X Genomics on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Mar
2019
Gottlieb Exits, Biogen’s Big Gene Therapy Buy, and Lilly’s Pre-Emptive Price Cut
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Mar
2019
Beam Therapeutics, Pushing The Edges in Base Editing, Raises $135M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Mar
2019
Pharma Dodges Senate Bullet, Roche Pays $4.8B for Spark, & BMS-Celgene Deal Wobbles
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Feb
2019
Third Rock, Arch Join at Hip, Lead $191M Bet on Maze and ‘Gene Modifiers’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Feb
2019
Staying Resilient, Finding a Way Forward: Julia Owens on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Feb
2019
The Boston Cancer Summit and SF Cancer Summit. See the Agenda & Get Your Tickets
The Boston Cancer Summit is loaded with a stellar lineup of speakers on Apr. 16. Same deal with the San Francisco Cancer Summit on Apr. 18. I’m excited to announce the agendas for these special idea-and-networking forums. Hal Barron of GSK, David Schenkein of GV, Cindy Perettie of Foundation Medicine, and Ira Mellman of Genentech are a few of the... Read More
15
Feb
2019
The PCSK9 Price Cut, J&J Depression Drug Passes Test, & Gilead’s NASH Strikeout
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.